MEA Haemostatic Agents Market

MEA Haemostatic Agents Market Size (2023 to 2028)

The size of the Haemostatic Agents Market in the Middle East and Africa is estimated to project a sluggish growth rate from 2023 to 2028.

The growing number of trauma and surgical cases, technological advancements, rise in the incidence of hemorrhage during surgery, and an increasing emphasis on blood control are a few factors accelerating the growth of the hemostatic agents market in the MEA region. In addition, Y-O-Y rise in the aging population and technological developments in surgical techniques are further anticipated to enhance the market's growth rate during the forecast period.

As the prevalence of chronic diseases, cesarean deliveries, fatal injuries, and significant organ surgeries has increased, so has the demand for hemostats. These drugs help patients with hemostatic disorders and nonanatomic and sensitive structures avoid blood loss during surgical operations. Apart from that, their use aids in reducing treatment expenses, which has resulted in broad adoption among healthcare professionals. Furthermore, prominent manufacturers have developed absorbable adjunctive hemostats that aid professionals in managing disruptive bleeding more successfully than previous approaches due to technological developments.

The high prevalence of blood clotting disorders in countries like the UAE and Kuwait and a lack of awareness about hemostatic diagnostics in MEA are projected to impede the market for hemostatic diagnostic analyzers and reagents. In addition, high per capita income in rural areas has expanded the usage of diagnostic and therapeutic agents, putting a burden on patient care. Furthermore, certain government standards and strict norms have been imposed to strengthen the healthcare infrastructure.

This research report on the Middle East and Africa Haemostatic Agents Market has been segmented and sub-segmented into the following categories:

• By Type: Thrombin Based Haemostats, Gelatin Based Haemostats, Collagen Based Haemostats, Oxidized Regenerated Cellulose Based Haemostats, Combination Haemostats, Fibrin Sealants, and Others
• By Treatment: Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery, and Others      
• By End User: Hospitals, Surgery Centres, Nursing Homes, and Others      
• By Country: KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Geographically, the Middle East and Africa accounted for a moderate global market share in 2022. The UAE government devotes a significant amount of its GDP to health care. According to the Organization for Economic Cooperation and Development, healthcare accounts for more than 18% of the country's GDP. According to a study published by the Centers for Disease Control and Prevention, the prevalence rate of hemophilia, a bleeding disorder, is 1 in every 5000 male births. Due to the fact that this illness can only be treated by surgery, proper bleeding control equipment is essential.

KEY MARKET PLAYERS:

Companies playing a vital role in the MEA Haemostatic Agents Market profiled in this report are Ethicon, Pfizer, Baxter International, R. Bard, The Medicines Company, Anika Therapeutics, Advanced Medical Solutions, Integra LifeSciences, B Braun Melsungen, Gelita Medical, Equimedical, Vascular Solutions, Marine Polymer Technologies, and Z-Medica.